exosomes exist bodily fluid include ah vh 10. vh high potential contain exosomal biomarkers pdr study focus vitreal exosomes present uveal melanoma 20 neovascular amd 21 dr 22. liu et al 22 demonstrate exosomes collect vh pdr patient could regulate angiogenesis retinal endothelial cell however none study discuss explore component vitreal exosomes pdr patient pdr endstage dr mainly cause retinal ischemia pathological neovascularization vitreoretinal interface exosomes significantly affect angiogenesis therefore promise effective therapeutic target pdr great importance obtain comprehensive proteomic profile vitreal exosomes pdr patient develop novel diagnostic prognostic biomarkers base exosomes therefore perform labelfree quantitative proteomics analysis compare protein profile human vitreal exosomes obtain pdr patient control subject study complete qilu hospital shandong university china research adhere provision declaration helsinki approve ethical review committee hospital patient consecutively enrol july 2020 september 2021 sign inform consent receive complete explanation nature possible consequence study pdr subject receive primary par plana vitrectomy ppv treatment vitreous haemorrhage preretinal membrane macular hole retinal detachment recruit pdr group nondiabetic control diagnose idiopathic macular epiretinal membrane idiopathic macular hole need ppv surgery recruit control group dr classification perform base visible ophthalmological change presence retinal neovascularization accord result multicentre early treatment diabetic retinopathy study detail past medical history subject collect use standard questionnaire exclude people ocular disease high myopia glaucoma retinal disease history previous ocular surgery exception mild cataract patient free systemic disorder e.g. malignant tumour hyperthyroidism ongoing infection addition patient type 2 diabetes mellitus t2dm uncontrolled systemic hypertension subject hyperlipemia hyperproteinaemia also exclude study prior initiate vitrectomy 1 ml nondilute vh harvest careful suction infusion use 25gauge vitrectomy nontransparent bloody sample collect blood serum sample obtain overnight fast early morning first day admission sample transfer dry ice store eppendorf tube 80 °c assay perform expression level triglyceride tg total cholesterol tcho highdensity lipoprotein cholesterol hdlc lowdensity lipoprotein cholesterol ldlc albumin alb globulin glb fast blood glucose fbg serum test clinical laboratory qilu hospital differential ultracentrifugation perform exosome isolation human vh sample describe previously 23. centrifugation step perform 4 °c brief 0.5 ml vh sample centrifuge 2000×g 10,000×g 30 45 min respectively 4 °c eliminate cellular debris supernatant filter twice 0.22 μm filter millipore move new tube exosomes pelleted ultracentrifugation 100,000×g 70 min mla55 fixedangle rotor beckman coulter brea ca usa pellet wash phosphatebuffered saline pb prevent protein contamination centrifuge 100,000×g 70 min pb remove exosomes resuspend 100 08l pb store 80 °c analysis bca assay thermo fisher scientific waltham usa perform total protein exosomes accord manufacturer 's protocol quantification exosomes perform use electron microscopy nanoparticle track analysis nta flow cytometry exosome count use normalise mass spectrometer m intensity detect mz exosome morphology observe use ultramicroscopic analysis brief freshly isolate exosome suspension fix 2 glutaraldehyde 4 °c overnight absorb onto copper grid copper grid exosomes fix 3 glutaraldehyde stain 4 uranyl acetate droplet grid eventually observe transmission electron microscope thermo fisher scientific 100 kv size concentration vesicle determine nta use nanosight ns300 system malvern uk follow manufacturer 's protocol without modification triplicate test perform value average derive size distribution concentration profile sample isolate vesicle confirm three typical exosomal marker cd9 cd63 cd81 fitc mouse antihuman antibody becton dickinson company usa use nanoscale flow cytometry nanofcm volume sample use throughout flow cytometric analysis 30 08l 1:4 dilute exosomes 20 08l fitc mouse antihuman cd9 cd63 cd81 macsquant analyzer 10 use nanofcm analysis strict accordance operate instruction one millilitre ripa lysis buffer add isolate exosomes lysate sonicated boil 15 min mixture centrifuge 14,000 g 15 min 4 °c supernatant transfer new tube quantify use bca assay thermo fisher scientific waltham usa equal amount protein 100 08g sample dilute 1 mgml alkylated prechilled acetone protein shake ice 30 min centrifuge 4 °c speed 1000 g. pellet wash twice 200 08l 80 chill acetone protein pellet mix 200 μl 1 sodium deoxycholate sdc 100 mm ammonium bicarbonate sonicated 30 min water bath dissolve protein pellet five millilitre tris 2chloroethyl phosphate add sample mix 55 °c 10 min 10 mm iodoacetamide add sample cool room temperature rt incubate 15 min darkness trypsin resuspend resuspension buffer 0.5 08g08l incubate rt 5 min trypsin solution add sample protein trypsin 50 1 incubate 37 °c thermomixer overnight supernatant carefully transfer new tube clean sdc desalt c trap column empore64 spe cartridge c18 sigma peptide concentrate vacuum centrifugation reconstitute 40 μl 0.1 vv formic acid lcmsms analysis lcmsms analysis perform use nanohplc easynlc1200 couple qexactive mass spectrometry thermo finnigan datadependent acquisition perform positive ion mode sample 2 μg peptide separate use reversedphase column 120 min gradient 300 nlmin flow rate orbitrap analyser set resolution 70,000 mz 200 range mz 3501400 ms1 ms2 resolution set 17,500 mz 200. isolation width 2 mz automatic gain control target set 1.0 e ms1 1.0 e ms2 top 20 intense ion select liner ion trap normalise collision energy 28 dynamic exclusion set 40 s. raw m data analyse maxquant software version 2.0.1.0. trypsin choose specific enzyme two miss cleavage oxidation acetyl protein nterm set variable modification carbamidomethyl c set fix modification precursor mass tolerance set 20 ppm maximum fragment mass error 0.8 da follow criterion protein identification unique protein false discovery rate fdr le 1 concurrent detection least two peptide differential protein target gene term gene ontology go database determine conduct go enrichment analysis include biological process bps molecular function mf cellular component cc significant go term determine use fisher 's exact test calculate p value correct fdr threshold correct p value ≤0.05 go term meet criterion regard significant term enrich differentially express protein kyoto encyclopedia gene genome kegg pathway enrichment analysis use identify biological function enrich pathway analysis base kegg pathway hypergeometric test calculate determine whether pathway enrich proteinprotein interaction perform use search tool retrieval interact genesproteins string database peptide separate use nanoflow ultraperformance liquid chromatography mass spectrometry system target quantification verification select protein analyse parallel reaction monitor prm analysis perform use qexactive hf mass spectrometer thermo scientific bremen germany 120 minsample transition set follow precursor charge 2 3 ion charge 1 2 ion type b autoselection match transition ion match tolerance 0.005 mz selection six intense product ion raw data collect use prm acquisition method normalise accord sum intensity statistical software graphpad prism graphpad prism version 5 use statistical analysis student 's ttest mannwhitney test perform appropriate compare two group independent sample categorical variable perform fisher 's exact test χ test differentially express protein two group identify abundance ratio pdrcontrols ≥2 ≤0.5 p value le 0.05 consider significant receiver operate characteristic roc analysis area curve auc use evaluate diagnostic value index p value le 0.05 consider significant data express mean ±